Search results for "biologic"
Article
Improving Capacity in DNA Plasmid Purification
Join Tony Hitchcock on May 6, 2020 to learn more about this critical market and how Cobra Biologics is working with Cytiva to develop a modern chromatography resin to help meet the demand.
Reg…
Article
Purposeful Design and Development of a Next-Generation Single-Use Bioprocess Film
Recognizing the need for a film constructed specifically to meet the complex bioprocessing nature of a multitude of biologics, Cytiva has developed Fortem™ film.
Fortem™ is purposefully des…
Article
The Evolution of Supply Chain Security: Increasing Focus on Raw Material Variability
An increase in the development of biological and patient-specific drugs has also reinforced the demand for heightened raw material control.
Click here to read more >>
Article
Purification of Plasmid DNA
By switching to modern chromatography resins, Cobra Biologics was able to increase binding capacity and flow rates up to 50% to address the increasing demands for high quality plasmid DNA.
Click h…
Article
Securing Today’s Biomanufacturing Supply Chain Using Transformative Supply
Today, biologics represent a $250 billion industry, which is two times what it was worth only 10 years ago. Though monoclonal antibodies are expected to continue dominating the market, a more divers…
Article
New Therapies Present Scaling Challenges
By Feliza Mirasol
The approval of emerging biologic-based therapeutics—such as cell and gene therapies—presents challenges and decisions for drug companies looking to increase the manu…
Article
A New Paradigm in Process Development
Accelerate biologic manufacturing of mAbs, vaccines, and novel biotherapies. Download this e-book for case studies and insights from Janssen, Roivant Sciences, and mAbxience.
Click here to downl…
Article
Tips for Viral Vector Production
The viral vector market is highly active, and the interest in production technologies is driven by recent approvals in cell and gene therapy. In this blog article, insights are shared around the cha…
Article
Design Considerations for a Commercial Cell and Gene Therapy Facility
For biologics and viral vectors, the cells are a byproduct of production and, thus, often get lysed and discarded in the downstream process, which is designed to optimize both the yield and the purity…
Poster
Reduce Risk of Failure in Your Virus Clearance Study by Choosing Robust Scale-Down Chromatography Tools
Effective viral clearance studies remain one of the challenges facing manufacturers of biologics. These studies are an essential part of process validation and are critical to ensure drug safety. Vi…